Durect Corp (NAS:DRRX)
$ 0.88 -0.0325 (-3.56%) Market Cap: 27.32 Mil Enterprise Value: 30.68 Mil PE Ratio: 0 PB Ratio: 22.56 GF Score: 60/100

DURECT Corp at H C Wainwright NASH Investor Conference (Virtual) Transcript

Oct 12, 2021 / 06:30PM GMT
Release Date Price: $12.9 (+7.50%)
Ed Arce
H.C. Wainwright & Co. - Analyst

Hello, and welcome to the H.C. Wainwright fifth annual NASH investor conference. My name is Ed Arce. I'm one of the senior biotech analysts here at H.C. Wainwright. And I am now very pleased to introduce our next presenting company, DURECT. And representing the Company is Jim Brown, the President and CEO; Mike Arenberg, the Chief Financial Officer; Dr. WeiQi Lin, the Executive Vice President of R&D and Principal Scientist; and last but not least, Dr. Norman Sussman, the Chief Medical Officer. Welcome, everyone.

Norman Sussman
DURECT Corporation - Chief Medical Officer

Hello, Ed.

Jim Brown
DURECT Corporation - President & CEO

Thank you, Ed. Thanks for having us here today.

Questions & Answers

Ed Arce
H.C. Wainwright & Co. - Analyst

Absolutely. Glad you could join us. So let's jump right in. Of course, those that have been following your story more recently would know that DUR-928 is your lead compound.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot